Recruiting
Phase 2

MRgART vs. LINAC

Sponsor:

University of Wisconsin, Madison

Code:

NCT07132918

Conditions

Non-Small Cell Lung Cancer (Stage III)

Esophageal Cancer Stage I-III

Esophagogastric Cancer Stage I-III

Thymoma and Thymic Carcinoma Stage II-III

Other Cancers in the Thoracic Region

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Interventions

MRgART

LINAC

Study Details

Brief summary:

The goal of this clinical trial is to compare a new way of using magnetic resonance-guided adaptive radiation therapy (MRgART) to the standard of care linear accelerator (LINAC) radiation treatment in people with cancer in the thoracic region near the heart.

The main question it aims to answer is whether MRgART affects the heart differently than LINAC.

Participants will:

  • Receive radiation therapy
  • Undergo MRIs and bloodwork
  • Complete quality of life questionnaires

Conditions

Non-Small Cell Lung Cancer (Stage III)

Esophageal Cancer Stage I-III

Esophagogastric Cancer Stage I-III

Thymoma and Thymic Carcinoma Stage II-III

Other Cancers in the Thoracic Region

Study ID

NCT07132918

Start date

Oct 8, 2025

Status verified date

Mar, 2026

Completion date

Mar, 2029

Anticipated

Primary completion date

Mar, 2029

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Age > 18 years at the time of consent.
  • Dosimetric eligibility criteria met using endpoints from QUANTEC (>10% of heart receives > 25 Gy) as determined through rapid auto-planning
  • Participants with histologically or cytologically proven AJCC, 8th edition including:

  • Stage IIB, IIIA, IIIB, IIIC, or IV non-operable non-small cell lung cancer
  • Limited stage small cell lung cancer, once daily treatment (excluding twice per day fractionation schemes). Stage I-III N0-2 disease esophageal/esophagogastric cancer
  • Stage II or III thymoma/thymic carcinoma
  • Other cancers in the thoracic region that meet the dosimetric and other clinical trial criteria, for example lymphoma sarcoma.
  • Participants must have a course of daily fractionated RT planned of at least 15 treatment fractions, typically ranging from 1.8 to 4 Gy/fraction

Exclusion Criteria:

  • Definitive clinical or radiologic evidence of metastatic disease with life expectancy <12 months
  • Prior thoracic radiotherapy significantly overlapping the heart region
  • Contraindications to MRI
  • Severe, active co-morbidity defined as follows: New York Heart Association Functional Classification III/IV are not eligible.

Study Design

Enrollment

60 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Arms

experimental: MRgART radiation therapy

Participants randomized to this arm will receive magnetic resonance-guided adaptive radiation therapy (MRgART)

experimental: LINAC radiation therapy

Participants randomized to this arm will receive linear accelerator (LINAC) radiation therapy

Interventions

MRgART

Magnetic Resonance-guided Adaptive Radiation Therapy (MRgART) is a form of MRgRT that incorporates daily adaptive planning, or making a new treatment plan each treatment, and real-time imaging during treatment delivery.

LINAC

Daily 3D x-ray scans will be obtained for radiation delivery to confirm tumor and organ at risk placement.

Primary outcome measure

  • Change in left ventricular ejection fraction (LVEF) [ Time Frame: Pre-treatment, 3 months post-treatment, 6 months post-treatment ]

Central Contacts and Locations

Central contacts

Cancer Connect

800-622-8922cancerconnect@uwcarbone.wisc.edu

Locations

University of Wisconsin - Madison

Recruiting

Madison, Wisconsin, United States, 53705

Contacts

Cancer Connect

800-622-8922cancerconnect@uwcarbone.wisc.edu

Principal Investigator:

Carri Glide-Hurst, PhD, DABR, FAAPM

More Information

Sponsor

University of Wisconsin, Madison

Last update posted

Mar 11, 2026

Last verified

Mar, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by University of Wisconsin, Madison on 2026-03-11.